The Maryland-based company biotech firm $Novavax(NVAX)$ Latest Earnings Results reported a Q1 net loss of $293.9 million and the company would slash its global workforce by about 25%.
Seems investors are wondering how will they going to do $1.5 billion in covid vaccine sales in 2023 after doing only $81 million in Q1.
Hopefully its staff cuts will contribute toward its goal of reducing its annual expenditure by around 40% to 50% by 2024, according to the press release.
However, the outlook of$Novavax(NVAX)$ is Neutural, good news shows the company has positive Phase 2 Topline results show on COVID-Influenza combination, stand-alone influenza and high-dose COVID vaccine candidates demonstrate robust immune responses.
After 35 years of business, Novavax’s Covid antidote remains its only commercially available product.
$Novavax(NVAX)$ soared 27.79% on Tuesday .
Option feld see much more trading enthusiasms, see from the news @Option_Movers There were 116.2K $Novavax(NVAX)$ option contracts traded on Tuesday, surging over 270% from the previous day. Call options account for 61% of overall option trades. Particularly high volume was seen for the $10 strike call option expiring May 12, with 7,874 contracts trading.with 50,343 contracts trading.
Regarding to $Novavax(NVAX)$’s option strategies, the public info shares If NVAX stock price at expiration is at or above $11.00, a spread strategy has a 42% upside potential.
The optimal stock price for this option strategy is to close at or above $11.00 on the expiration date, May 12, 2023. In that scenario, both calls would be in-the-money, so the spread would be worth the maximum value of 3.00. That would equate to the potential upside of +37% for this call spread with 3 days left to expiration.
The maximum gain will be realized if the stock price is at or above 11.00. The maximum gain is $0.81
The breakeven point is at 10.19, which is 7.7% below the current spot price.
The maximum loss will occur when the stock price is at or below 8. The max loss is $2.19.
I’m learning about trading options……
Comments
Despite the challenges, Novavax's Phase 2 results for COVID-Influenza combination and influenza vaccines look promising
NVAX oversold again...! Eyes on ACRX tomorrow, out tonight from ACRX
Novavax stock skyrocketed by 27.79% on Tuesday, and option trading saw a significant surge in enthusiasm
I hope the staff cuts at Novavax help them reduce expenses and meet their targets by 2024
Whoa, Novavax reported a massive Q1 net loss and plans to cut a quarter of its workforce
Check for tomorrow morning's conference details on the Novavax website.